Advertisement
BAX vs MDT
Which Stock Would AI Choose? Baxter International (BAX) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- Baxter International (BAX) reported first-quarter 2026 sales of $2.7 billion with an adjusted earnings per share (EPS) beat, while Medtronic (MDT) prepares for fiscal fourth-quarter results expected June 3, 2026.
- BAX stock has shown recent volatility with post-earnings gains followed by pullbacks, trading near $18.78, whereas MDT has experienced sharper year-to-date declines, closing around $73.81.
- BAX operates primarily in renal care, medication delivery, and acute therapies with a smaller market capitalization, while MDT offers broader exposure across cardiovascular, diabetes, and surgical technologies.
- Both companies face sector pressures including margin dynamics and regulatory scrutiny, though BAX reaffirmed full-year 2026 guidance after its recent results.
- MDT benefits from larger scale and diversified revenue streams, potentially offering relative stability compared to BAX's more concentrated business lines amid ongoing turnaround efforts.
- Relative performance highlights trade-offs in growth consistency versus near-term catalysts, with neither stock demonstrating clear dominance in recent market activity.
Introduction
This comparison examines Baxter International (BAX) and Medtronic (MDT), two established players in the healthcare equipment and supplies sector. Investors and traders focused on medical technology and devices may find this analysis relevant when evaluating relative positioning within a mature industry influenced by innovation cycles, reimbursement trends, and macroeconomic factors. The assessment draws on recent financial disclosures, stock price movements, and sector dynamics to highlight contrasts in scale, business focus, and market responses without projecting future outcomes.
BAX Overview and Recent Performance
Baxter International (BAX) provides products and therapies in areas such as renal care, medication delivery, and acute therapies. In recent weeks, the company reported first-quarter 2026 results showing sales from continuing operations of $2.7 billion, up 3% on a reported basis but down 1% organically, alongside an adjusted EPS of $0.36 that exceeded consensus estimates. Management reaffirmed full-year 2026 guidance for flat to 1% reported sales growth. Stock behavior reflected initial positive reaction to the earnings beat followed by subsequent pullbacks amid broader margin and regulatory considerations, with shares trading near $18.78 as of late May 2026. Sentiment has been shaped by cost initiatives and volume recovery efforts in core segments.
MDT Overview and Recent Performance
Medtronic (MDT) develops medical devices across cardiovascular, diabetes, neuroscience, and surgical portfolios. The company is scheduled to report fiscal fourth-quarter 2026 results on June 3, 2026, with analyst expectations centered on revenue around $9.6 billion and EPS near $1.54. In recent market activity, shares have traded lower, closing around $73.81 amid year-to-date pressures and sector-wide movements. Performance reflects ongoing portfolio expansion and demand in key platforms, tempered by competitive and regulatory factors. Market positioning emphasizes scale advantages in a diversified medical technology business.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots from hundreds available that trade thousands of tickers. Only those demonstrating strong alignment with prevailing market conditions earn placement in this section. Bots exhibit varied trading styles, strategies, timeframes, and performance statistics, with many tracking metrics such as win rates, drawdowns, and profitability ranges that can fluctuate based on market regimes. This resource allows users to explore data-driven approaches tailored to specific assets and conditions. Explore Trending AI Robots for additional details on available options.
Head-to-Head Comparison
Baxter International (BAX) maintains a focused portfolio in renal and acute care therapies, contrasting with Medtronic (MDT)’s broader platform spanning multiple therapeutic areas and larger global footprint. Growth drivers for BAX center on operational improvements and new product contributions following recent earnings, while MDT draws from sustained demand across cardiovascular and surgical segments. Recent momentum shows BAX with shorter-term rebounds tied to quarterly results, versus MDT’s more pronounced longer-term price adjustment amid fiscal year-end anticipation. Risk factors include debt levels and margin pressures for BAX alongside competitive intensity and reimbursement dynamics for MDT. Sector exposure overlaps in healthcare equipment, yet MDT’s scale may provide greater resilience in volatile environments compared to BAX’s more specialized positioning.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, trend stability, and relative sector positioning in recent periods, Tickeron’s AI models would likely assign a modest probabilistic preference to Medtronic (MDT) over Baxter International (BAX) at present. MDT’s diversified revenue base and upcoming quarterly visibility could support steadier sentiment compared to BAX’s ongoing turnaround dynamics, though outcomes remain contingent on broader market conditions and execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a StrongBuy and MDT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 0 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s).
- BAX’s FA Score: 0 green, 5 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 5 TA indicator(s) are bullish while MDT’s TA Score has 5 bullish TA indicator(s).
- BAX’s TA Score: 5 bullish, 4 bearish.
- MDT’s TA Score: 5 bullish, 5 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а -5.53% price change this week, while MDT (@Medical/Nursing Services) price change was -1.38% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.83%. For the same industry, the average monthly price growth was -0.55%, and the average quarterly price growth was -14.44%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.01%. For the same industry, the average monthly price growth was -3.66%, and the average quarterly price growth was -16.13%.
Reported Earning Dates
BAX is expected to report earnings on Jul 23, 2026.
MDT is expected to report earnings on Aug 25, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-1.83% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| BAX | MDT | BAX / MDT | |
| Capitalization | 10.2B | 101B | 10% |
| EBITDA | 750M | 9.36B | 8% |
| Gain YTD | 2.982 | -16.805 | -18% |
| P/E Ratio | 87.85 | 21.25 | 413% |
| Revenue | 11.3B | 35.5B | 32% |
| Total Cash | 2.02B | 8.38B | 24% |
| Total Debt | 9.69B | 28.1B | 34% |
BAX | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 95 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 74 | |
PRICE GROWTH RATING 1..100 | 49 | 61 | |
P/E GROWTH RATING 1..100 | 36 | 62 | |
SEASONALITY SCORE 1..100 | 35 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is significantly better than the same rating for BAX (95). This means that MDT’s stock grew significantly faster than BAX’s over the last 12 months.
MDT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that MDT’s stock grew similarly to BAX’s over the last 12 months.
MDT's SMR Rating (74) in the Medical Specialties industry is in the same range as BAX (96). This means that MDT’s stock grew similarly to BAX’s over the last 12 months.
BAX's Price Growth Rating (49) in the Medical Specialties industry is in the same range as MDT (61). This means that BAX’s stock grew similarly to MDT’s over the last 12 months.
BAX's P/E Growth Rating (36) in the Medical Specialties industry is in the same range as MDT (62). This means that BAX’s stock grew similarly to MDT’s over the last 12 months.
| BAX | MDT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 52% |
| Momentum ODDS (%) | N/A | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 49% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 45% |
| Advances ODDS (%) | 12 days ago 55% | 8 days ago 51% |
| Declines ODDS (%) | 8 days ago 65% | 16 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 54% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 55% |
Advertisement
BAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with ALGN. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | -1.16% | ||
| ALGN - BAX | 64% Loosely correlated | -4.57% | ||
| LUNG - BAX | 53% Loosely correlated | -0.78% | ||
| STE - BAX | 51% Loosely correlated | -1.09% | ||
| SYK - BAX | 51% Loosely correlated | -1.01% | ||
| XRAY - BAX | 47% Loosely correlated | -1.74% | ||
More | ||||
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.